Jaguar Health Inc (JAGX)
4.22
-0.07
(-1.63%)
USD |
NASDAQ |
May 31, 16:00
4.30
+0.08
(+1.90%)
After-Hours: 20:00
Jaguar Health Cash from Financing (Quarterly): 12.27M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.27M |
| December 31, 2023 | 10.65M |
| September 30, 2023 | 1.409M |
| June 30, 2023 | 3.357M |
| March 31, 2023 | 18.81M |
| December 31, 2022 | 1.638M |
| September 30, 2022 | 10.15M |
| June 30, 2022 | 3.246M |
| March 31, 2022 | 8.15M |
| December 31, 2021 | 3.121M |
| September 30, 2021 | 0.373M |
| June 30, 2021 | 9.575M |
| March 31, 2021 | 30.87M |
| December 31, 2020 | 10.80M |
| September 30, 2020 | 1.253M |
| June 30, 2020 | 5.414M |
| March 31, 2020 | 2.023M |
| December 31, 2019 | 4.953M |
| September 30, 2019 | 9.003M |
| June 30, 2019 | 4.347M |
| March 31, 2019 | 3.469M |
| Date | Value |
|---|---|
| December 31, 2018 | 6.744M |
| September 30, 2018 | 1.125M |
| June 30, 2018 | -0.00 |
| March 31, 2018 | 16.68M |
| December 31, 2017 | 5.369M |
| September 30, 2017 | 2.546M |
| June 30, 2017 | 2.712M |
| March 31, 2017 | 0.0527M |
| December 31, 2016 | 1.388M |
| September 30, 2016 | 1.172M |
| June 30, 2016 | -1.228M |
| March 31, 2016 | 3.951M |
| December 31, 2015 | -0.25M |
| September 30, 2015 | 5.856M |
| June 30, 2015 | 17.32M |
| March 31, 2015 | 1.24M |
| December 31, 2014 | 0.92M |
| September 30, 2014 | -0.7741M |
| June 30, 2014 | 1.252M |
| March 31, 2014 | 4.676M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.373M
Minimum
Sep 2021
30.87M
Maximum
Mar 2021
7.570M
Average
5.184M
Median
Cash from Financing (Quarterly) Benchmarks
| BioSig Technologies Inc | 1.54M |
| BioVie Inc | 15.98M |
| Entero Therapeutics Inc | 3.379M |
| Genprex Inc | 6.793M |
| Adial Pharmaceuticals Inc | 3.824M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.047M |
| Free Cash Flow | -30.34M |
| Free Cash Flow Per Share (Quarterly) | -2.662 |
| Free Cash Flow to Equity (Quarterly) | -3.30M |
| Free Cash Flow to Firm (Quarterly) | -6.436M |
| Free Cash Flow Yield | -611.7% |